PD-1/PD-L1 inhibitors monotherapy vs. combination therapy in elderly advanced NSCLC: a real-world study and nomogram for survival prognosis
Abstract Background Immunotherapy with PD-1/PD-L1 inhibitors has transformed advanced non-small cell lung cancer (NSCLC) treatment, yet optimal strategies for elderly patients remain uncertain. Elderly patients (≥ 65 years) exhibit immune senescence (e.g., T-cell dysfunction, chronic inflammation),...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2025-07-01
|
| Col·lecció: | BMC Pulmonary Medicine |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s12890-025-03791-x |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|